Hepatotoxicity
Conditions
Keywords
pharmacogenetics, anti-tuberculosis drug, genetic polymorphism, isoniazid
Brief summary
To improve the treatment outcome in patients with tuberculosis and integrate the pharmacogenetics into clinical practice, the information of NAT2 genotyping was used in re-challenge protocol for isoniazid (INH) titration in patients with anti-tuberculosis medication-induced hepatitis.
Interventions
DRUGisoniazid
dose adjustment according to the pharmacogenomic results
Sponsors
National Taiwan University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. \>= 18 years. 2. Take INH for at least a week. 3. abnormal liver function (ALT (alanine, transaminase) increased by more than three times the upper limit of normal, or ALT higher than twice the upper limit of normal and total bilirubin higher than 2.0 mg / dL
Exclusion criteria
1.Taking INH before liver function abnormalities. 2.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| successful re-use of isoniazid for TB treatment | 6 months | In this study, we would like to test the hypothesis of NAT2 genotyping helping in isoniazid rechallenge after patients experienced adverse effects of anti-TB treatment. Therefore, to observe the patients can re-use isoniazid successfully is an important outcome measure in this study. |
Countries
Taiwan
Contacts
Primary ContactLi-Jiuan Shen, Ph.D.
Outcome results
None listed